A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in
outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are
required to undergo a washout period of at least 7 days of any prior med.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.